Switzerland's DocMorris H1 revenue rises on RX growth, raises 2026 outlook

DocMorris AG

19/08/2026 06:11

Overview
Switzerland online pharmacy's H1 external revenue rose 12.5% yr/yr
Adjusted EBITDA loss narrowed by CHF 17.9 mln compared to prior year
Company raised 2026 revenue and adjusted EBITDA guidance after strong H1 performance

Outlook
DocMorris now sees 2026 external revenue growth of 9% to 13%
Company expects 2026 adjusted EBITDA between minus CHF 10 mln and minus CHF 17.5 mln
DocMorris confirms target of EBITDA breakeven in second half of 2026

Result Drivers
RX GROWTH - Revenue from prescription medicines rose sharply, driven by higher customer loyalty, repeat orders, and new customer acquisition
DIGITAL SERVICES - Digital Services revenue increased 71.4%, with TeleClinic and other platforms contributing to above-average earnings growth
MARKETING EFFICIENCY - Improved marketing efficiency in Rx business contributed to higher profitability

Company press release: ID:nEQ9V9S7Ha

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 External Revenue
 
CHF 627.80 mln
 
H1 Adjusted EBITDA
 
-CHF 10.90 mln
 
H1 EBIT
 
-CHF 40.90 mln
 
H1 EBITDA
 
-CHF 20 mln
 

Reuters Recommended Reads
Aug 18 - Switzerland's Basilea H1 revenue rises on Cresemba demand; ups 2026 profit outlook
Aug 18 - China's Ping An Healthcare H1 revenue profit jumps on corporate client base expansion
Aug 17 - Mobile healthcare provider DocGo's Q2 revenue misses on wind-down of migrant programs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)